Baseline — Bipolar Disorder Stable on a Mood Stabilizer
Patient euthymic for months on a stabilizing regimen before conception.
- ~1–2%: Lifetime prevalence (reproductive-age women)
- ~5%: Baseline relapse rate (per year, stable treatment)
- Li / VPA / LTG: Common stabilizers (lithium, valproate, lamotrigine)
- Months: Pre-pregnancy euthymia (typical stable interval)
Why baseline stability matters
A stable baseline sets the reference point for measuring later risk.
Role of maintenance medication
Continuous stabilizer use is the main protective factor against relapse.
Pregnancy — Mood Stabilizer Discontinued or Reduced
Teratogenicity concerns, especially with valproate, often prompt dose changes.
- ~10%: Valproate teratogen risk (major malformations)
- ~50%: Discontinuation rate (stop meds in pregnancy)
- 2× baseline: Relapse after stop (during pregnancy)
- Weeks: Time to relapse (after abrupt taper)
Teratogenicity tradeoffs
Clinicians balance fetal risk against maternal mood stability.
Abrupt vs. gradual taper
Rapid discontinuation raises relapse risk more than slow tapering.
Postpartum Begins — Severe Sleep Deprivation from Newborn Care
Fragmented sleep and disrupted circadian rhythm start immediately after birth.
- 3–8×: Nightly wakings (typical newborn care)
- 2–4 hrs: Sleep lost per night (first postpartum weeks)
- Potent: Sleep loss as trigger (known mood destabilizer)
- High: Circadian disruption (irregular light/dark exposure)
Sleep loss and mood circuitry
Circadian disruption is one of the strongest known episode triggers.
Newborn care demands
Feeding schedules fragment sleep across the full night cycle.
Combined Risk — Medication Gap Plus Sleep Deprivation
Unmedicated status and severe sleep loss together multiply relapse probability.
- ~4–5×: Combined risk vs baseline (both factors unfavorable)
- Superadditive: Interaction effect (not simply additive)
- Weeks 0–6: Highest-risk window (postpartum)
- >50%: Untreated + sleepless risk (episode within months)
Why risks compound
Each factor alone destabilizes mood; together they interact sharply.
Clinical monitoring window
Early postpartum weeks demand closest symptom surveillance.
Postpartum Bipolar Relapse — Mania, Depression, or Mixed Episode
Postpartum relapse risk markedly exceeds non-postpartum periods for bipolar patients.
- ~40–67%: Postpartum relapse rate (unmedicated patients)
- ~7×: Risk vs non-postpartum (elevated period)
- Strong: Postpartum psychosis link (bipolar-associated risk)
- Substantial: Mitigation impact (planning + sleep protection)
Episode types observed
Mania, depression, and mixed presentations all occur postpartum.
Mitigation strategies
Medication planning and protected sleep reduce relapse substantially.
Care team coordination
Psychiatry, obstetrics, and family support lower overall risk.